Vaishali Verma

Dr. Vaishali Verma


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2024 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
ARAbhavya Raja
Abhavya Raja
AKAbhishek Kasana
Abhishek Kasana
VVVaishali Verma
Vaishali Verma

9 April 2025 in mAbs
Verified
Journal Article
Open access
VVVaishali Verma
Vaishali Verma
NSNimisha Sinha
Nimisha Sinha
ARAbhavya Raja
Abhavya Raja
Viral infections remain a significant global health threat, with emerging and reemerging viruses causing epidemics and pandemics. Despite advancements in antiviral therapies, the development of effective treatments is often hindered by challenges, such as viral resistance and the emergence of new strains. In this context, the development of novel therapeutic modalities is essential to combat notorious viruses. While traditional monoclonal antibodies are widely used for the treatment of several diseases, nanobodies derived from heavy chain-only antibodies have emerged as promising "nanoscale warriors" against viral infections. Nanobodies possess unique structural properties that enhance their ability to recognize diverse epitopes. Their small size also imparts properties, such as improved bioavailability, solubility, stability, and proteolytic resistance, making them an ideal class of therapeutics for viral infections. In this review, we discuss the role of nanobodies as antivirals against various viruses. Techniques used for developing nanobodies, delivery strategies are covered, and the challenges and opportunities associated with their use as antiviral therapies are discussed. We also offer insights into the future of nanobody-based antiviral research to support the development of new strategies for managing viral infections.

25 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
Cho Yeow KohCho Yeow Koh
Cho Yeow Koh
NSNorrapat Shih
Norrapat Shih
CYChristina Y. C. Yip
Christina Y. C. Yip
ALAaron Wei Liang Li
Aaron Wei Liang Li
WCWeiming Chen
Weiming Chen
MCMark Y Chan
Mark Y Chan
Despite their limitations, unfractionated heparin (UFH) and bivalirudin remain standard-of-care parenteral anticoagulants for percutaneous coronary intervention (PCI). We discovered novel direct thrombin inhibitors (DTIs) from tick salivary transcriptomes and optimised their pharmacologic activity. The most potent, ultravariegin, inhibits thrombin with a Ki of 4.0 pM, 445-fold better than bivalirudin. Unexpectedly, despite their greater antithrombotic effect, variegin/ultravariegin demonstrated less bleeding, achieving a 3-to-7-fold wider therapeutic index in rodent thrombosis and bleeding models. When used in combination with aspirin and ticagrelor in a porcine model, variegin/ultravariegin reduced stent thrombosis compared with antiplatelet therapy alone but achieved a 5-to-7-fold lower bleeding time than UFH/bivalirudin. Moreover, two antibodies screened from a naïve human antibody library effectively reversed the anticoagulant activity of ultravariegin, demonstrating proof-of-principle for antidote reversal. Variegin and ultravariegin are promising translational candidates for next-generation DTIs that may reduce peri-PCI bleeding in the presence of antiplatelet therapy.

1 January 2022 in Journal of Applied Biology & Biotechnology
Verified
Journal Article
Open access
PDF file
VVVaishali Verma
Vaishali Verma
Over the past two decades, several technologies have become available to rapidly develop therapeutic monoclonal antibodies (MAbs) against any target of interest. Consequently, antibodies have emerged as key biologics for the treatment of various forms of cancer, autoimmune diseases, and infectious diseases. Antimicrobial resistance (AMR) is a condition, wherein the microbes evolve and stop responding to the available treatment options. The development of AMR makes it harder to treat infections resulting in increased severity of disease, deaths, and risk of infection spread. Driven by the misuse of antibiotics, globally, there has been a consistent spread of multi- and pan-resistant bacteria that are untreatable with the existing antibiotics. Unfortunately, the emergence of AMR bacteria outpaces the rate at which new antibiotics are being discovered. Therefore, due to the ever-increasing burden of AMR, there is an unmet need for next-generation strategies to combat infections. With the approval of several MAbs for the treatment of various conditions and three MAbs for the treatment of bacterial infections, they are currently being explored as a therapeutic alternative for the treatment of AMR bacteria. It is envisaged that antibody-based drugs can be administered as a standalone therapy or as an adjunct therapy in combination with antibiotics for improved efficacy and hold promise to address the problem of AMR. This review describes the strategies employed for the development of antibody-based drugs and discusses the MAbs that are already approved as therapeutics or are at various stages of the drug development pipeline for the treatment of bacterial infections.

1 January 2025 in Journal of Applied Biology & Biotechnology
Verified
Journal Article
Open access
PDF file
AKAbhishek Kasana
Abhishek Kasana
ADAishwarya Dwivedi
Aishwarya Dwivedi
VVVaishali Verma
Vaishali Verma
Viruses cause infectious diseases in humans, ranging from mild to life-threatening. Early and accurate diagnosis is essential for timely treatment and prevention of complications. Diagnostic methods typically rely on detecting viral genetic material, proteins, or the host’s immune response, depending on the infection stage. Monoclonal antibodies, known for their specificity and high affinity, are widely used for diagnosing viral infections by enabling precise and sensitive detection of viral proteins. This review explores the applications of monoclonal antibody-based methods for detecting viral infections, emphasizing their pivotal role as sensitive detection reagents. These methods are crucial for developing robust immunodiagnostic assays capable of diagnosing various viral diseases in human, animal, and plant hosts, with special emphasis on SARS-CoV-2. The review also explores various assays that employ monoclonal antibodies for diagnostic purposes and the technologies used for their production. Understanding the principles and applications of monoclonal antibodies in diagnosing viral diseases is essential for implementing effective public health interventions and preventing future pandemics.

8 January 2024 in Air Quality, Atmosphere & Health
Verified
Journal Article
Closed access
PDF file
PBPriyadharshini B
Priyadharshini B
VVVaishali Verma
Vaishali Verma
SKSwapna Sarika Khadanga
Swapna Sarika Khadanga
SYShailendra Yadav
Shailendra Yadav
BDBharath Kumar Dudam
Bharath Kumar Dudam
AGAyushi Gupta
Ayushi Gupta